文拉法辛缓释剂治疗躯体形式疼痛障碍疗效观察  

Effect of venlafaxine XR in the treatment of persistent somatoform pain disorder

作　　者：黄东[1] 何晓艳[1] 郑秀霞[1] 杨左兵[1] 黄建新[1] 

机构地区：[1]福建省闽清精神病防治院,350800

出　　处：《精神医学杂志》2009年第6期437-439,共3页Journal of Psychiatry

摘　　要：目的探讨文拉法辛缓释剂治疗躯体形式疼痛障碍的疗效及不良反应。方法将67例躯体形式疼痛障碍患者随机分成文拉法辛缓释片组和多塞平组,分别治疗6周。采用医学结局研究用疼痛量表(MOSPM)、Hamilton抑郁量表(HAMD)、焦虑量表(HAMA)及副反应量表(TESS)评定疗效及不良反应。结果文拉法辛缓释片组和多塞平组有效率分别为68.6%、71.9%,两组比较无显著性差异(P>0.05)。治疗后6周末文拉法辛缓释片组和多塞平组MOSPM、HAMD及HAMA评分与治疗前比较均有极显著性差异(P<0.01),但文拉法辛缓释片组在治疗1周末MOSPM评分就明显下降,与治疗前比较有显著性差异(P<0.05),且文拉法辛缓释片组药物副反应少而轻,多塞平组抗胆碱方面副作用明显。结论文拉法辛缓释片治疗躯体形式疼痛障碍疗效显著,不良反应轻,依从性好。Objective To explore the efficacy and side effects of venlafaxine XR in the treatment of persistent somatoform pain disorder. Methods A total of 67 patients with persistent somatoform pain disorder randomly divided into venlafaxine XR group and doxepine group, for the treatment of 6 weeks. The Medical Outcomes Study Pain Measurement （MOSPM）, Hamilton Depression Scale （HAMD）, Hamilton Anxiety Scale （HAMA） and Treatment Emergent Symp- tom Scale（TESS） were used to evaluate efficacy and side effects. Results The efficacy rates of venlafaxine XR group and doxepine group were 68.6% and 71.9% respectively. There was no significant difference between two groups（P 〉 0.05）. The scores of MOSPM, HAMD and HAMA at the 6th weekend after treatment decreased significantly compared with those of baseline in both groups（P 〈0.01）. But the score of MOSPM in venlafaxine XR group at the lstweekend was significantly lower than that of baseline （ P 〈 0.05 ）. The side effeets were fewen and milder in venlafaxine XR group, doxepine group had significant anticholinergic side effects. Conclusion Venlafaxine XR is effective in the treatment of persistent somatoform pain disorder with milder side effects and better compliance.

关 键 词：躯体形式疼痛障碍 文拉法辛缓释片 多塞平 

分 类 号：R749.7[医药卫生—神经病学与精神病学]